

Carbon Reduction Plan

Parent organisation: Glenmark Pharmaceuticals Limited

Bidding entity: Glenmark Pharmaceutical Europe Limited

Publication date:April 2024.....

Commitment to achieving Net Zero

Glenmark Pharmaceuticals Limited (including Glenmark Pharmaceuticals Europe Limited to which this carbon reduction plan also applies), is committed to achieving Net Zero emissions by 2050.

The environmental measures set out below are able to be applied to and will be adopted by Glenmark Pharmaceuticals Europe Limited when performing the relevant contract.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions.

Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2020-21	
Additional Details relating to the Baseline Emissions calculations.	
Baseline year emissions:	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	13,331
Scope 2	71,717
Scope 3 (Included Sources)	1,76,551 (Included Categories of Purchased goods and services, Capital Goods, Fuel and energy related activities, Upstream transportation and distribution, Waste generated in operations, Business Travel, Employee commuting, downstream transportation and distribution)

Total Emissions	2,61,599
------------------------	----------

Current Emissions Reporting

Reporting Year: 2022-23	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	13,118
Scope 2	68,903
Scope 3 (Included Sources)	175,069 Purchased goods and services, Capital Goods, Fuel and energy related activities, Upstream transportation and distribution, Waste generated in operations, Business Travel, Employee commuting, downstream transportation and distribution
Total Emissions	2,57,090

Emissions reduction targets


In order to continue our progress to achieving Net Zero, we have adopted the following carbon reduction targets.

We project that carbon emissions (Scope 1 + 2) will decrease over the next five years to 70165 tCO₂e by 2028 from the year 2023. This is a reduction of 14%

Glenmark Pharmaceuticals Limited also commits to reduce scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, downstream transportation and distribution, and investments by 28% per ton of pharmaceutical products by 2035.

Progress against these targets can be seen in the graph below:

Carbon Reduction Plan Projection by 2050 vs Actual



Carbon Reduction Projects

Completed Carbon Reduction Initiatives

The following environmental management measures and projects have been completed or implemented since the FY2021 baseline. The carbon emission (Scope 1+2) reduction achieved by these schemes equate to 3027 tCO₂e, a 3.6%ge reduction against the 2021 baseline till FY2023 and the measures will be in effect when performing the contract

In the future we hope to implement further measures such as:

REPORTING YEAR: FY23		
TARGET YEAR	PLANNED AND REALISED ACTIVITY TO REACH TARGET tCO ₂ e	SOURCE(S) THESE WILL ADDRESS
2030	<p>To emerge as a Carbon Neutral enterprise by 2030 (Scope 1 and 2) India locations. We aim to become carbon neutral through focused decarbonisation initiatives. Planned activities:-</p> <ul style="list-style-type: none"> • We are making continuous improvements in this regard such as shifting to cleaner sources of fuel for our operations, becoming more energy efficient and increasing the share of renewable energy in our mix and using refrigerant with lower emissions. <ul style="list-style-type: none"> ○ Installation of briquette boilers ○ Using lower emission refrigerants ○ Reducing requirement for electricity: <ul style="list-style-type: none"> ▪ AHU EC fans ▪ Energy efficient motors ▪ Heat Pump Improvements ▪ HVAC Digitalization ○ Adopting greener electricity sources such as renewable energy usage for electricity – Solar / Wind / Hybrid. <p>Realised activities: -</p> <ul style="list-style-type: none"> • Use of cleaner fuel like Biofuel in operations at our 2 facilities. We have installed LPG Yard at our facilities which is used for hot water generator operations & for steam generation for boiler operations. • Implementation of power purchase agreements for hydro-power open access as a renewable source of energy at our 2 facilities. Approximately, there is 60 – 70% of renewable energy consumption out of total consumption in these 2 facilities. • Installation of a heat pump at our 2 facilities to replace electrical heaters for humidity control • Automated dust collector operation with remote control 	<p>Scope 1</p> <ul style="list-style-type: none"> • Fuels (including gaseous, liquid, solid fuels, biofuels, biomass and bio-gas) • Refrigerants and other gases (carbon dioxide, methane, nitrous ox etc.) <p>Scope 2</p> <ul style="list-style-type: none"> • Electricity purchased

	<ul style="list-style-type: none"> • Digitization of HVAC system is in progress to maintain precise air quality and achieve energy saving • Installation of motion sensors for office lighting • Optimised AHU operation during non-working hours by installing timer control • Optimised operation of HVAC system during non-working hours of manufacturing, packing sampling & dispensing areas • Optimised operation of dust collector system during non-working hours of production & packing areas • Installation of energy saving fans for Utility cooling towers • Elimination of pre-heating requirement of Furnace Oil (replaced with Biofuel). • Installation of flash vessel to utilize flash steam from Agitated Thin Film Drier (ATFD) • Installation of steam purging system with feed water tank in Boiler house to raise boiler feed water temperature • Installation of steam condensate recovery system and used recovered hot water to heat boiler feed water. • Use of chemical (frigitech) in chiller system to improve cooling efficiency • Reduction in compressed air requirement by installing air regulators in washing areas. • Interconnection of two hot water generators to optimize the operation to using one unit at a time. 	
<p>2035</p>	<p>Approved target from SBTi Glenmark Pharmaceuticals Limited commits to reduce absolute scope 1 and 2 GHG emissions by 35% by FY2035 from a FY2021 base year. Glenmark Pharmaceuticals Limited also commits to reduce scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, downstream transportation and distribution, and investments by 28% per ton of pharmaceutical products within the same timeframe. This is in line with a well below 2 degree C trajectory.</p> <p>The above initiatives mentioned in the Carbon neutral target will also be applicable here for consideration. In addition to this, we have also</p>	<p>Scope 1</p> <ul style="list-style-type: none"> • Fuels (including gaseous, liquid, solid fuels, biofuels, biomass and bio-gas) • Refrigerants and other gases (carbon dioxide, methane, nitrous ox etc.) <p>Scope 2</p> <ul style="list-style-type: none"> • Electricity purchased

	planned to reduce material based emissions, supply chain emissions in order to reduce Scope 3 emissions.	Scope 3 <ul style="list-style-type: none"> • Purchased goods and services • Fuel- and energy-related activities • Downstream transportation and distribution • Investments
--	--	---

Declaration and Sign Off


This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Parent Company:



Glenmark Pharmaceuticals Limited

Date: 17-04-2024

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>